Glybera Registry, long-term safety and efficacy follow-up in Lipoprotein Lipase deficient (LPLD) patients treated with alipogene tiparvovec (GLYBERA®) First published 02/04/2013 Last updated 15/03/2024 EU PAS number:EUPAS3750 Study Finalised